(Press-News.org) “What should I eat?” is perhaps the most common question patients with inflammatory bowel disease ask their doctors.
It’s notoriously difficult to answer. There have been few large studies of dietary interventions for IBD, a group of disorders that includes ulcerative colitis and Crohn’s disease.
Now, new research by Stanford Medicine investigators and their colleagues provides one potential answer. Their national, randomized controlled clinical trial found that a short-term, calorie-restrictive diet significantly improved both physical symptoms and biological indicators of mild-to-moderate Crohn’s disease. The findings will be published Jan. 13 in Nature Medicine.
While dietary interventions are difficult to study — participants’ reports of what they’re eating aren’t always accurate, and the placebo effect can’t be avoided because participants know which diet they’re on — the findings were notable, demonstrating significant declines in objective markers of inflammation in biologic samples alongside improvements in clinical symptoms. The study may help physicians guide patients in finding a diet that alleviates symptoms.
“We have been very limited in what kind of dietary information we can provide patients,” said Sidhartha R. Sinha, MD, an assistant professor of gastroenterology and hepatology and the senior author on the paper. “This study will give physicians evidence to support recommendations in an area that patients are very curious about.”
A common condition, few treatments
A chronic condition affecting about a million Americans, Crohn’s disease causes inflammation in the digestive tract, leading to symptoms of diarrhea, cramping, abdominal pain and weight loss. Steroids are the only approved therapeutic for mild Crohn’s, but their use is limited due to significant side effects, particularly with long-term use.
The study compared the symptoms and biological indicators of patients with mild-to-moderate Crohn’s disease as they either followed a fasting mimicking diet or ate their normal diet for three consecutive months. The study enrolled 97 patients across the country, with 65 in the fasting mimicking group and 32 in the control group.
Participants in the fasting mimicking group severely limited their calories for five consecutive days per month, eating between about 700 and 1,100 calories a day, Sinha said. Plant-based meals were provided during the fasting period. For the remainder of the month, the fasting mimicking group ate their normal diet.
At the end of the study, about two-thirds of the fasting mimicking group experienced improvement in their symptoms. “We were very pleasantly surprised that the majority of patients seemed to benefit from this diet,” Sinha said. “We noticed that even after just one FMD cycle, there were clinical benefits.”
In the control group, less than half experienced improvements in their symptoms. The improvement was likely a result of natural symptom fluctuations in Crohn’s disease and because patients continued to follow their standard care regimens, such as taking medications.
Some participants in the fasting mimicking group experienced fatigue and headache, Sinha said, but no serious side effects were reported.
Biological indicators get a boost
Sinha was inspired to study the fasting mimicking diet in patients with Crohn’s disease after earlier research indicated the diet could reduce levels of C-reactive protein, a common marker of systemic inflammation in patients who had high baseline C-reactive protein levels. “The effects seen on inflammatory markers made this an appealing diet to study in Crohn’s disease since many patients with this disease also have elevated inflammatory markers,” he said.
Along with tracking participants’ clinical response and remission, the researchers also explored changes in biological specimens, such as shifts in common markers of inflammation in both stool and blood. “Our goal in collecting these and other biospecimens was to dig deeper into why there’s this differential response,” Sinha said. “Can we find mechanisms to explain the findings and signatures that might help predict patients who will respond to the diet?”
The researchers found a significant decline in fecal calprotectin, a protein in the stool that indicates gut inflammation, in the fasting mimicking group compared with the control group. Some inflammation-promoting lipid mediators derived from fatty acids also declined in fasting mimicking group participants. Similarly, the immune cells of fasting mimicking group participants produced fewer of several types of inflammatory molecules. The researchers are now exploring whether changes in the gut microbiome may also help explain some of the benefits of the fasting mimicking diet.
“There’s still a lot more to be done to understand the biology behind how this and other diets work in patients with Crohn’s disease,” Sinha said.
The study’s first authors are Stanford Medicine’s Chiraag Kulkarni, MD, an instructor in gastroenterology and hepatology, and assistant clinical research coordinator Touran Fardeen.
Researchers from the University of Southern California and the University of California, San Francisco, contributed to the work.
Author Valter Longo, PhD, has equity interest in L-Nutra, the company from which the fasting mimicking meals were purchased and has filed patents related to the diet.
This work was supported by a grant from The Leona M. and Harry B. Helmsley Charitable Trust, the National Institutes of Health (grants UM1TR004921, 2L30 DK126220, T32DK007056, K08DK134856 and NIDDK R01DK085025), the Plant Based Diet Initiative at Stanford University, the Kenneth Rainin Foundation, the Doris Duke Foundation Physician Scientist Fellowship Award, a CZ Biohub Physician Scientist Scholar Award, the Colleen and Robert D. Hass fund, and the Chan-Zuckerberg Biohub Investigator Program.
# # #
About Stanford Medicine
Stanford Medicine is an integrated academic health system comprising the Stanford School of Medicine and adult and pediatric health care delivery systems. Together, they harness the full potential of biomedicine through collaborative research, education and clinical care for patients. For more information, please visit med.stanford.edu.
END
The number of vehicles in Africa is expected to double between now and 2050 – faster than on any other continent. The question is not whether mobility will increase, but how. A new study led by researchers at ETH Zurich and the Paul Scherrer Institute PSI, in collaboration with African partners from Makerere University, University of Port Harcourt and Stellenbosch University, shows that electric vehicles, combined with solar-powered off-grid charging systems, could be economically competitive in many African countries well before 2040.
“Many models have assumed that combustion engine vehicles will continue to dominate in Africa through ...
A test that rapidly detects signs of inflammatory bowel disease (IBD) in stool samples could improve future diagnosis and monitoring of the condition, a study suggests.
Scientists have developed a tool to measure the activity of a molecule linked to gut inflammation within faecal samples.
The optical tool, known as a luminescent reporter, lights up when it detects the molecule, with higher readouts indicating increased activity and inflammation.
The new technique could boost the accuracy of stool sample tests for IBD, reducing the need ...
Widely-used eye ointments can cause glaucoma implants to swell and potentially rupture, according to new research from Nagoya University in Japan. This study is the first to show, using clinical and experimental evidence, that petrolatum-based eye ointments can compromise the PRESERFLO® MicroShunt, an implant used in over 60 countries to treat glaucoma.
Glaucoma is an eye disease that damages the optic nerve and can lead to vision loss. It often results from increased intraocular pressure caused by blocked drainage of eye fluid. A recent study estimated that 76 million ...
Amsterdam, 13 January 2026. Today, the ACCESS-AD consortium is announcing the launch of a transformative European initiative that will accelerate the implementation of scientific innovations for Alzheimer’s disease (AD) management in real-world health systems. The international consortium - bringing together academic institutions, industry partners, SMEs and patient organisations - is co-led by Amsterdam UMC, Siemens Healthineers, King’s College London and Gates Ventures, with funding from the European Commission’s Innovative Health Initiative for a five-year period.
The project begins at a pivotal moment for AD care in Europe. In 2025, two new disease-modifying therapies ...
A new study led by researchers at the University of Waterloo found that members of many Indigenous communities who eat certain types of locally harvested waterfowl, especially ducks with mixed or fish-based diets, may have higher levels of both mercury and healthy omega-3 fatty acids in their blood.
The research, conducted in partnership with northern First Nations communities, suggests that waterfowl, such as ducks and geese, may need to be included more regularly in monitoring programs that track both contaminants and nutrients in traditional foods.
“Traditional foods ...
Scientists have discovered that a part of the brain may be behind high blood pressure.
The lateral parafacial region sits in the brainstem – the oldest part of the brain – which controls automatic functions such as digestion, breathing, and heart rate.
“The lateral parafacial region is recruited into action causing us to exhale during a laugh, exercise or coughing,” says lead researcher Professor Julian Paton, director of Manaaki Manawa, Centre for Heart Research at Waipapa Taumata Rau, University of Auckland.
“These ...
A faulty ion channel function is a consistent biological feature of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), providing long-awaited validation for hundreds of thousands of Australians living with the debilitating illness.
The new Griffith University research found a crucial cellular structure responsible for calcium transport, the TRPM3 ion channel, was faulty in immune cells from people with ME/CFS.
Director and senior author, Professor Sonya Marshall-Gradisnik from Griffith’s National Centre for Neuroimmunology and Emerging Diseases (NCNED), said the TRPM3 played an essential role in calcium transport into cells, regulating responses properly ...
Scientists have discovered that blocking a key cellular enzyme thought to protect against fatty liver disease may instead increase the risk of chronic liver damage and cancer as we age.
In a major new study published in Science Advances, researchers from Adelaide University have shown that loss of the enzyme Caspase-2 drives abnormal growth in liver cells, triggering inflammation, fibrosis, and a significantly higher risk of liver cancer.
The findings challenge growing interest in Caspase-2 inhibitors as a potential therapeutic strategy to treat and/or prevent fatty liver disease and highlight the need for caution when targeting this ...
Kyoto, Japan -- What we know of the birth of a black hole has traditionally aligned with our perception of black holes themselves: dark, mysterious, and eerily quiet, despite their mass and influence. Stellar-mass black holes are born from the final gravitational collapse of massive stars several tens of the mass of our Sun which, unlike less massive stars, do not produce bright, supernova explosions.
Or at least, this is what astronomers had previously thought, because no one had observed in real time the collapse of a massive star leading to a supernova and forming a black hole. That is, until a team of researchers at Kyoto University reported their observations of SN 2022esa.
The ...
The research group of Professor Chuandong Dou at the State Key Laboratory of Supramolecular Structure and Materials, Jilin University, recently constructed two novel boron-hexane two-dimensional benzobenzenes using a borane-controlled cyclization strategy, elucidating the importance of boron atom doping. Using conjugated boranes as precursors, the researchers synthesized boron-hexane Z-type and bilayer benzobenzenes C32B2 via FeCl3 and Bi(OTf)3-mediated intramolecular cyclization reactions, obtaining narrow-spectrum fluorescence (half-width at half-maximum as narrow as 19 nm) and amplified spontaneous emission properties, demonstrating their ...
